Contact
searchSearch
HMP Global
Login

Value-Based Care Topic Center

Featured

JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
News
ONCare Alliance Emerges as a Transformative Force in Independent Oncology and Cancer Care
02/29/2024

Brandon Twyford

Brandon Twyford
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care...
02/29/2024
Cancer Care Business Exchange
From Cancer Care Business Exchange
Editor in chief Winston Wong, PharmD.
Editor Insights
Looking at 2023 Key Trends and Insights to Navigate the Future of Value-Based Care
02/13/2024
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways
Engaging Payers
How to Support the Adoption and Integration of Specialty Value-Based Care Models: A Conversation Across Multiple Stakeholders
02/09/2024
Lili Brillstein, MPH, discusses key points from the 2023 Healthcare Innovations Summit held in Aspen, Colorado, regarding the barriers to implementing value-based care models for specialty care, and what can be done to overcome them and...
Lili Brillstein, MPH, discusses key points from the 2023 Healthcare Innovations Summit held in Aspen, Colorado, regarding the barriers to implementing value-based care models for specialty care, and what can be done to overcome them and...
Lili Brillstein, MPH, discusses...
02/09/2024
Journal of Clinical Pathways
David F. Lobach, MD, PhD, MS
Videos
How Patient-Centered Cancer Symptom Management Can Help Improve Patient Outcomes
01/25/2024
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice...
01/25/2024
Journal of Clinical Pathways
Mary E. Cooley, PhD, RN, FAAN
Videos
Clinical Decision Support in Cancer Care: Why the Patient’s Voice Matters
01/24/2024
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN,...
01/24/2024
Journal of Clinical Pathways
Harlan Levine, MD
Videos
Expanding Access to Care Through Academic-Community Cancer Care Collaboration
01/23/2024
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights...
01/23/2024
Journal of Clinical Pathways
Kianta Key
Videos
Strategies the Health Care Industry Can Implement to Improve Black Women’s Participation in Clinical Trials
12/28/2023
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice...
12/28/2023
Journal of Clinical Pathways
News
CPC & CBEx Keynote Session: How Do We Define Value-Based Oncology Care?
10/07/2023
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the...
10/07/2023
Journal of Clinical Pathways

Expert Insights

JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Editor in chief Winston Wong, PharmD.
Editor Insights
Looking at 2023 Key Trends and Insights to Navigate the Future of Value-Based Care
02/13/2024
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways
David F. Lobach, MD, PhD, MS
Videos
How Patient-Centered Cancer Symptom Management Can Help Improve Patient Outcomes
01/25/2024
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice...
01/25/2024
Journal of Clinical Pathways
Mary E. Cooley, PhD, RN, FAAN
Videos
Clinical Decision Support in Cancer Care: Why the Patient’s Voice Matters
01/24/2024
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN,...
01/24/2024
Journal of Clinical Pathways
Harlan Levine, MD
Videos
Expanding Access to Care Through Academic-Community Cancer Care Collaboration
01/23/2024
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights...
01/23/2024
Journal of Clinical Pathways
Kianta Key
Videos
Strategies the Health Care Industry Can Implement to Improve Black Women’s Participation in Clinical Trials
12/28/2023
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice...
12/28/2023
Journal of Clinical Pathways
Theresa Dreyer, MPH
Videos
Perspective on Lessons Learned from Academic Practices Participating in OCM
06/30/2023
Theresa Dreyer, MPH, value-based care team lead for the Association of American Medical Colleges (AAMC), shares further insights from her ASCO 2023 presentation and discusses the benefits and challenges for academic practices participating in...
Theresa Dreyer, MPH, value-based care team lead for the Association of American Medical Colleges (AAMC), shares further insights from her ASCO 2023 presentation and discusses the benefits and challenges for academic practices participating in...
Theresa Dreyer, MPH, value-based...
06/30/2023
Journal of Clinical Pathways
Lalan Wilfong, MD.
Conference Coverage
Benefits and Challenges of the Enhancing Oncology Model
06/13/2023
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting,...
06/13/2023
Journal of Clinical Pathways
Jacqlyn Riposo
Quality Outlook
Focus on Outcomes: Quality Measurement Recommendations for CMS’ Medicaid Cell and Gene Therapy Access Model
06/08/2023
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers...
06/08/2023
Journal of Clinical Pathways
Sawsan Rashdan, MD
Videos
Future Directions in NSCLC Care: Navigating Pathways, Costs, and Cutting-Edge Therapies
11/14/2024
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate...
11/14/2024
Journal of Clinical Pathways
Videos
Evolving Oncology Pathways, CLL Treatment Advances, and the Role of Multidisciplinary Care Teams
11/12/2024
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD,...
11/12/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Videos
Assessing Fixed-Duration Obinutuzumab, Ibrutinib, and Venetoclax in CLL: A 7-Year Follow-Up
11/08/2024
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a...
11/08/2024
Journal of Clinical Pathways
BDHC Thumbnail
Breaking Down Health Care
Navigating Payer Challenges in Cell and Gene Therapy
11/07/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health...
11/07/2024
Cancer Care Business Exchange
Videos
Navigating Multidisciplinary Care: Insights on Oncology Practice Integration and Pharmaceutical Partnerships
11/04/2024
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at...
11/04/2024
Journal of Clinical Pathways
Videos
Custom Pathways in Oncology: Innovations, Stakeholder Collaboration, and Value-Based Care
11/01/2024
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice...
11/01/2024
Journal of Clinical Pathways
Interview
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
10/30/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
10/30/2024
Journal of Clinical Pathways
JB
Interview
The Road Ahead for CLL Research and Treatment: Overcoming Challenges and Embracing Innovations in Patient Care
10/25/2024
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements...
10/25/2024
Journal of Clinical Pathways
Jessica Paulus, ScD
Interview
Insights on Lung Cancer Diagnosis Trends and Screening Challenges in Community Oncology
10/23/2024
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica...
10/23/2024
Journal of Clinical Pathways
Federico Cappuzzo, MD, National Cancer Institute Regina Elena
Videos
The Impact of Subcutaneous Formulation of Atezolizumab on Treatment for Patients with Non-Small Cell Lung Cancer
10/17/2024
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses...
10/17/2024
Oncology

Newsfeed

News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
ONCare Alliance Emerges as a Transformative Force in Independent Oncology and Cancer Care
02/29/2024

Brandon Twyford

Brandon Twyford
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care...
02/29/2024
Cancer Care Business Exchange
News
CPC & CBEx Keynote Session: How Do We Define Value-Based Oncology Care?
10/07/2023
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the...
10/07/2023
Journal of Clinical Pathways
News
Regional Variations Detected in Clinical Trial Outcomes in Oncology
09/13/2022
Registration trials focused on oncology are expanding in number and are continually enrolling patients from many different countries and regions; according to findings from a recently published study, regional outcome variations occur in more...
Registration trials focused on oncology are expanding in number and are continually enrolling patients from many different countries and regions; according to findings from a recently published study, regional outcome variations occur in more...
Registration trials focused on...
09/13/2022
Journal of Clinical Pathways
News
Cancer Care Spending in the US May Not Be Proportionate With Better Cancer Outcomes
09/01/2022
Findings from a recent cross-sectional study of national cancer care expenditures and cancer mortality rates across 22 high-income countries indicate that although the cancer mortality rate in the US was lower than the median, the US spent...
Findings from a recent cross-sectional study of national cancer care expenditures and cancer mortality rates across 22 high-income countries indicate that although the cancer mortality rate in the US was lower than the median, the US spent...
Findings from a recent...
09/01/2022
Journal of Clinical Pathways
News
Trends for Identifying Regulator and Payer Evidence Needs in Development of Oncology Drugs
08/26/2022
Amy McKee, MD, Head of Regulatory Oncology, Parexel, and Alex Gee, Senior Director, Pricing and Market Access, Parexel, provided information about recent advancements in evidence needed to support oncology drug development and shared insights...
Amy McKee, MD, Head of Regulatory Oncology, Parexel, and Alex Gee, Senior Director, Pricing and Market Access, Parexel, provided information about recent advancements in evidence needed to support oncology drug development and shared insights...
Amy McKee, MD, Head of...
08/26/2022
Journal of Clinical Pathways
News
Labcorp Announces Spinoff of Clinical Development Business
08/26/2022
In a recent press release, the top global life sciences company, Labcorp, announced its decision from its Board of Directors to move forward with a spinoff of the company’s wholly owned Clinical Development business to shareholders of Labcorp...
In a recent press release, the top global life sciences company, Labcorp, announced its decision from its Board of Directors to move forward with a spinoff of the company’s wholly owned Clinical Development business to shareholders of Labcorp...
In a recent press release, the...
08/26/2022
Journal of Clinical Pathways
News
Projected Medicare Basic Part D Average Premium for 2023 Announced
08/26/2022
In a recent press release, the Centers for Medicare and Medicaid Services (CMS) announced that the average basic monthly premium for standard Medicare Part D coverage is predicted to be nearly $31.50 in 2023, a reduction of 1.8% from $32.08...
In a recent press release, the Centers for Medicare and Medicaid Services (CMS) announced that the average basic monthly premium for standard Medicare Part D coverage is predicted to be nearly $31.50 in 2023, a reduction of 1.8% from $32.08...
In a recent press release, the...
08/26/2022
Journal of Clinical Pathways
News
Examining Therapy Utilization and Quality of Care at Skilled Nursing Facilities Under Patient Driven Payment Model
08/16/2022
Findings from a recent study suggest that skilled nursing facilities responded to the patient driven payment model with changes in individual occupational therapy and physical therapy utilization, but no changes in rates of discharge to the...
Findings from a recent study suggest that skilled nursing facilities responded to the patient driven payment model with changes in individual occupational therapy and physical therapy utilization, but no changes in rates of discharge to the...
Findings from a recent study...
08/16/2022
Journal of Clinical Pathways
News
Defining the Notion of Value in Oncology Treatment
07/07/2022
A recent article discusses oncology-specific considerations when assessing elements of value, offering some background on the nature and development of quality-adjusted life-years as a part of cost-effectiveness analyses and some of their key...
A recent article discusses oncology-specific considerations when assessing elements of value, offering some background on the nature and development of quality-adjusted life-years as a part of cost-effectiveness analyses and some of their key...
A recent article discusses...
07/07/2022
Journal of Clinical Pathways
News
Enhancing Survival in Endometrial Cancer: Impact of Immunotherapy and Chemotherapy Combination Therapy
11/13/2024
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with...
11/13/2024
Journal of Clinical Pathways
News
Under 50% of Oncology Practices Offer Survivorship Clinics
11/12/2024
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice...
11/12/2024
Journal of Clinical Pathways
News
Experts Reach Consensus on Myelofibrosis Management, Offering New Hope for Patients
11/08/2024
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international...
11/08/2024
Journal of Clinical Pathways
News
Advancing Personalized Treatment in Endometrial Cancer With the HECTOR Deep Learning Model
11/06/2024
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published...
11/06/2024
Journal of Clinical Pathways
News
Influence of Socioeconomic and Demographic Factors on Myelofibrosis Outcomes
10/30/2024
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic...
10/30/2024
Journal of Clinical Pathways
News
Hypertension and Endometrial Cancer Risk: A Systematic Review and Meta-Analysis
10/25/2024
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and...
10/25/2024
Journal of Clinical Pathways
News
Harnessing the Potential of Abemaciclib in Recurrent Endometrial Cancer Treatment
10/25/2024
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor...
10/25/2024
Journal of Clinical Pathways
News
Pembrolizumab Plus Adjuvant Chemotherapy for Newly Diagnosed High-Risk dMMR Endometrial Cancer
10/21/2024
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with...
10/21/2024
Journal of Clinical Pathways
News
False Negatives More Prevalent in Endometrial Cancer Screening for Black Women
10/17/2024
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA...
10/17/2024
Journal of Clinical Pathways
News
Efficacy of Momelotinib in Managing Anemia in Myelofibrosis: Results from the SIMPLIFY-2 Trial
10/16/2024
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in...
10/16/2024
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Ipilimumab for the Treatment of Metastatic Melanoma
07/29/2021
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line...
07/29/2021
Journal of Clinical Pathways
Quiz
Quiz: Discussing Treatment Costs With Patients
03/12/2021
03/12/2021
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
News
ONCare Alliance Emerges as a Transformative Force in Independent Oncology and Cancer Care
02/29/2024

Brandon Twyford

Brandon Twyford
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care...
02/29/2024
Cancer Care Business Exchange
Editor in chief Winston Wong, PharmD.
Editor Insights
Looking at 2023 Key Trends and Insights to Navigate the Future of Value-Based Care
02/13/2024
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use